Login
$ONC
$370.87 -$6.76 (1.79%) Close

Company Executives

$ONC Management Team

Directors
7
serving now
Independent
5 of 5
stated in the proxy; 2 not stated
Average tenure
6.3 years
from year joined
CEO also chairs the board
Yes
John V. Oyler
Director Age On board Independent Committees Other public boards 2025 pay Source
Olivier Brandicourt
70 2024
2 years
Independent None stated Alnylam Pharmaceuticals, Inc. Not stated
Margaret Dugan
69 2022
4 years
Independent None stated None stated Not stated
Anthony C. Hooper
71 2020
6 years
Independent None stated MannKind Corporation $528,129
John V. Oyler
58 2010
16 years
Not stated None stated None stated Paid as CEO
Alessandro Riva
65 2022
4 years
Independent None stated Century Therapeutics, Inc. Not stated
Shalini Sharp
51 2024
2 years
Independent None stated Neurocrine Biosciences, Inc. $525,165
Xiaodong Wang
63 2016
10 years
Not stated None stated Clover Biopharmaceutical, Ltd. Not stated
Nominated to join at the meeting
Not on the board yet; they join only if elected.

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

Amgen
Amount not stated
October 31, 2019

Collaboration Agreement under which the company commercializes Amgen oncology products in China and the parties share profits and losses equally

With BeOne Medicines I GmbH Open in proxy
Amgen
Up to US$1.25 billion

Global oncology pipeline collaboration with co-funding of development costs, with BeOne Switzerland contributing up to US$1.25 billion

With BeOne Medicines Ltd. Open in proxy
Amgen
Aggregate purchase price of US$2.78 billion
January 2, 2020

Share Purchase Agreement under which the company issued 206,635,013 ordinary shares (15,895,001 ADSs) to Amgen

Amgen
Amgen owns approximately 17.05% of the Company’s outstanding share capital
US$199,280 per month
January 17, 2025

Sublease of property in San Carlos, California from an Amgen affiliate for research facilities and office space

With ChemoCentryx, Inc. Open in proxy
Shandong Luye Pharmaceutical Co., Ltd.
may be deemed to be a related party under Item 404 of Reg. S-K due to Hillhouse Investment Management, Ltd. and related entities being a significant shareholder of both BeOne Medicines Ltd. and Luye
Amount not stated
December 2022

Exclusive license agreement for BAITUOWEI in mainland China with upfront license payment and prepayment

With BeOne Open in proxy
Cayman Gaoyue
may be deemed to be a related party under Item 404 of Reg. S-K due to Hillhouse Capital Management, Ltd. and related entities being a significant shareholder of both BeOne and Cayman Gaoyue
Company’s total capital contribution to BeiGene Shanghai amounted to US$57,000,000, while Cayman Gaoyue contributed US$3,000,000
August 2023

Joint venture through BeiGene Shanghai with capital contributions by BeOne HK and Cayman Gaoyue

With BeOne HK Open in proxy
Shanghai Gaoyue Management Consulting Co., Ltd.
may be deemed to be a related party under Item 404 of Reg. S-K due to Hillhouse Capital Management, Ltd. and related entities being a significant shareholder of both BeOne Medicines Ltd. and Shanghai Gaoyue
RMB 3,660,000
July 2023

Service agreement for construction project due diligence and project management services, with extension

With BeOne Medicines Ltd. Open in proxy
Cayman Gaoyue
may be deemed to be a related party under Item 404 of Reg. S-K due to Hillhouse Capital Management, Ltd. and related entities being a significant shareholder of both BeOne and Cayman Gaoyue
US$3,253,130.34
December 2025

Share repurchase of all BeiGene Shanghai shares held by Cayman Gaoyue

With BeOne HK Open in proxy
Dr. Xiaodong Wang
Co-Founder, Chair of our Scientific Advisory Board and director
Annual fixed consulting fee of US$100,000

Consulting agreement providing for an annual fixed consulting fee

Pi Health Inc.
Payments totaling US$52,000,000
November 2023

Master services agreement, statements of work and subscription agreement with Pi Health for FICS implementation and clinical services, with payments totaling US$52,000,000

With BeOne Medicines USA, Inc. Open in proxy
Pi Health Inc.
An annual fee of US$300,000
September 27, 2024

Subscription and services agreement with Pi Health USA, LLC with an annual fee

With Pi Health USA, LLC Open in proxy
John V. Oyler
BeOne’s Co-Founder, Chairman and Chief Executive Officer; holds less than 20% of the total outstanding shares of Pi Health Inc.
Invested $1.8 million in Pi Health and will invest an additional $1.8 million
January 2026

BeOne Medicines I GmbH preferred stock purchase in Pi Health Series Seed funding, with a further investment contingent on milestones

With Pi Health Inc. Open in proxy
Diana Lee
spouse of Chan Lee, our Senior Vice President, General Counsel and Corporate Secretary
Approximately $174,999
March 2026 and April 2026

Order forms under master services agreement for data analytics support services provided by Constellation

With Constellation Software Inc. Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support